

**ANIMALS, CELLS AND METHODS FOR PRODUCTION OF
DETECTABLY-LABELED ANTIBODIES**

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority under 35 U.S.C. § 119(e) to provisional application serial no. 60/241,053, filed October 17, 2000, which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The invention is directed to methods for obtaining detectably-labeled antibodies to any antigen by using genetically-modified mammals which express at least one detectably-labeled antibody molecule component.

BACKGROUND OF THE INVENTION

Antibodies are widely used for diagnostic and research purposes for localizing an antigen within a cell, tissue, or other biological sample. For histopathology or cytology, cells are usually first exposed to a primary antibody which is specific for the desired target antigen but not directly detectable. In a subsequent step, the primary antibody is detected with a labeled secondary antibody which recognizes the primary antibody. This procedure is somewhat cumbersome and may result in undesirable background staining due to non-specific reactivity of the secondary antibody. In addition, in order to visualize two or more antigens, the primary antibodies must be from two different species such that each secondary antibody is not cross-reactive; expensive species-specific secondary antibodies must therefore be used for each primary antibody. With

1 advances in optical and digital imaging and detection, multiply-labeled samples and
2 simultaneous detection of several analytes is possible, yet the aforementioned biological
3 limitations do not permit full advantage to be taken of these advances. Moreover, since
4 99monoclonal antibodies are generated typically only in mice and rats, in conventional dual or
5 triple labeling, only one antibody can be monoclonal. This can be an important restriction.

6
7 Several techniques are available to circumvent these limitations, including direct chemical
8 conjugation of the primary antibody with a detectable molecule, or direct conjugation with biotin
9 and subsequence detection with a fluorescent avidin. These procedures are cumbersome and
10 requires purification of the primary antibodies.

11
12 It is towards the facile preparation of a detectable primary antibody to any desired antigen that
13 the present invention is directed.

14
15 The citation of any reference herein should not be construed as an admission that such reference
16 is available as "Prior Art" to the instant application.

17 18 SUMMARY OF THE INVENTION

19 In one broad aspect, the invention is directed to a genetically-modified mammal capable of
20 expressing at least one chimeric immunoglobulin gene comprising at least one detectable protein
21 or peptide fused with a gene expressing an immunoglobulin component selected from the group
22 consisting of the kappa immunoglobulin light chain, the lambda immunoglobulin light chain, an

1 immunoglobulin heavy chain, and any combination thereof, wherein antibodies secreted by
2 immune cells of the genetically-modified mammal comprise said at least one detectable protein
3 or peptide. The immunoglobulin heavy chain gene may be IgG, IgM, IgD or IgA. In one
4 embodiment, the at least one detectable peptide or protein is present at the C-terminus of the
5 gene product of the fusion polynucleotide; preferably, the at least one detectable peptide or
6 protein present at the C-terminus of the gene product of the fusion polynucleotide is located in
7 exon G1. In another embodiment, the at least one detectable peptide or protein is present at the
8 C-terminus of the gene product of the fusion polynucleotide with a flexible linker peptide
9 therebetween. Preferably, the least one detectable peptide or protein present at the C-terminus of
10 the gene product of said fusion polynucleotide with a flexible linker therebetween is located in
11 exon G1.

12
13 In one embodiment, the immunoglobulin molecule secreted by immune cells of the above-
14 mentioned genetically-modified mammal comprises at least one detectable protein or peptide in
15 the heavy chain of the immunoglobulin molecule. In another embodiment, the immunoglobulin
16 molecule secreted by immune cells of the genetically-modified mammal comprises at least one
17 detectable protein or peptide in the light chain of said immunoglobulin molecule. In a further
18 embodiment, the immunoglobulin molecule secreted by immune cells of the genetically-modified
19 mammal comprises at least one detectable protein or peptide in the heavy chain and at least one
20 detectable protein or peptide in the light chain of said immunoglobulin molecule.

21
22 In one embodiment of the invention, at least one of the aforementioned detectable proteins or

1 polypeptides is an autofluorescent protein or peptide, a visibly-detectable protein or peptide, an
2 enzymatically active protein or peptide, a protein or peptide capable of interacting with another
3 molecule to produce a detectable product, or any combination thereof. In another embodiment,
4 the detectable protein or polypeptide is capable of quenching or modulating fluorescence. Non-
5 limiting examples of autofluorescent proteins or peptides include green fluorescent protein, red
6 fluorescent protein, and a fluorescent analog or fragment of any of the foregoing. Green
7 fluorescent protein is preferred. In another embodiment, the at least one detectable protein is a
8 combination of an autofluorescent protein or peptide and an enzymatically-active protein or
9 peptide, such as but not limited to a combination of green fluorescent protein and alkaline
10 phosphatase.

11 In another broad aspect of the invention, a genetically-modified immune cell is provided which is
12 capable of expressing at least one chimeric immunoglobulin gene comprising at least one
13 detectable protein or peptide fused with a gene expressing an immunoglobulin component
14 selected from the group consisting of the kappa immunoglobulin light chain, the lambda
15 immunoglobulin light chain, an immunoglobulin heavy chain, and any combination thereof,
16 wherein antibodies secreted by the genetically-modified immune cell comprise the at least one
17 detectable protein or peptide. The immunoglobulin heavy chain gene may be IgG, IgM, IgD or
18 IgA. In one non-limiting example, the at least one detectable peptide or protein is present at the
19 C-terminus of the gene product of the fusion polynucleotide; preferably, the polynucleotide
20 encoding the at least one detectable peptide or protein present at the C-terminus of the gene
21 product of said fusion polynucleotide is located in exon G1. In another embodiment, the at least
22

1 one detectable peptide or protein present at the C-terminus of the gene product of said fusion
2 polynucleotide has a flexible linker peptide therebetween; preferably, the polynucleotide
3 encoding the at least one detectable peptide or protein present at the C-terminus of the gene
4 product of said fusion polynucleotide with a flexible linker therebetween is located in exon G1.

5
6 The immunoglobulin molecule secreted by the aforementioned immune cell may comprise at
7 least one detectable protein or peptide in the heavy chain of the immunoglobulin molecule, or it
8 may comprise at least one detectable protein or peptide in the light chain of said immunoglobulin
9 molecule. In another embodiment, the immunoglobulin molecule secreted by the genetically-
10 modified immune cells described above comprises at least one detectable protein or peptide in
11 the heavy chain and at least one detectable protein or peptide in the light chain of the
12 immunoglobulin molecule.

13
14 The aforementioned genetically-modified immune cell may have at least one detectable protein
15 or polypeptide that is capable of quenching or modulating fluorescence; or the protein or peptide
16 is an autofluorescent protein or peptide, a visibly-detectable protein or peptide, an enzymatically
17 active protein or peptide, a protein or peptide capable of interacting with another molecule to
18 produce a detectable product, or any combination thereof. In the example wherein the at least
19 one detectable protein is an autofluorescent protein or peptide, it may be, by way of non-limiting
20 example, green fluorescent protein, red fluorescent protein, or a fluorescent analog or fragment of
21 any of the foregoing. Green fluorescent protein is preferred. In another embodiment, the at least
22 one detectable protein is a combination of an autofluorescent protein or peptide and an

1 enzymatically-active protein or peptide, such as but not limited to a combination of green
2 fluorescent protein and alkaline phosphatase.

3
4 The invention is also directed to a hybridoma comprising the genetically-modified immune cell
5 as mentioned above.

6
7 In yet another aspect, the invention is directed to a chimeric, detectably-labeled immunoglobulin
8 molecule comprising at least one detectable protein or peptide fused with the kappa
9 immunoglobulin light chain, the lambda immunoglobulin light chain, an immunoglobulin heavy
10 chain, or any combination thereof. The at least one detectable peptide or protein may be present
11 at the C-terminus of the gene product of said fusion polynucleotide, preferably located in exon
12 G1. A flexible linker peptide may be provided therebetween. In another embodiment, a
13 polynucleotide encoding said at least one detectable peptide or protein present at the C-terminus
14 of the gene product of said fusion polynucleotide with a flexible linker therebetween is located in
15 exon G1. The chimeric, detectably-labeled immunoglobulin molecule may have an
16 immunoglobulin heavy chain gene is selected from IgG, IgM, IgD and IgA. At least one
17 detectable protein or peptide may be present in the heavy chain of said immunoglobulin
18 molecule, the at least one detectable protein or peptide may be present in the light chain of said
19 immunoglobulin molecule, or, in a further embodiment, the at least one detectable protein or
20 peptide may be present in the heavy chain and at least one detectable protein or peptide in the
21 light chain of said immunoglobulin molecule.

1 The aforementioned chimeric, detectably-labeled immunoglobulin molecule may have at least
2 one detectable protein or polypeptide that is capable of quenching or modulating fluorescence;
3 or, the at least one detectable protein or peptide is an autofluorescent protein or peptide, a
4 visibly-detectable protein or peptide, an enzymatically active protein or peptide, a protein or
5 peptide capable of interacting with another molecule to produce a detectable product, or any
6 combination thereof. In one embodiment, the at least one detectable protein is an autofluorescent
7 protein or peptide, such as but not limited to green fluorescent protein, red fluorescent protein, or
8 a fluorescent analog or fragment of any of the foregoing. Preferably, it is green fluorescent
9 protein. In another embodiment, the at least one detectable protein may be a combination of an
10 autofluorescent protein or peptide and an enzymatically-active protein or peptide, such as but not
11 limited to a combination of green fluorescent protein and alkaline phosphatase.

12
13 In a further broad aspect, the present invention provides a method for producing a quantity of
14 detectably-labelled polyclonal antibodies by carrying out at least the steps of

- 15 a) providing a genetically-modified mammal as described hereinabove;
- 16 b) immunizing the genetically-modified mammal with a preselected immunogen,
17 wherein the genetically-modified mammal generates antibodies to the
18 immunogen, wherein antibodies secreted by immune cells of the genetically-
19 modified mammal comprise the at least one detectable protein or peptide; and
- 20 c) isolating the detectably-labelled antibodies from the genetically-modified
21 mammal.

1 The invention is also directed to a method for producing a quantity of detectably-labelled
2 monoclonal antibodies comprising the steps of

- 3 a) preparing a genetically-modified mammal in accordance with the above
4 description;
- 5 b) immunizing the genetically-modified mammal with a preselected immunogen,
6 wherein immune cells of the genetically-modified mammal generate antibodies to
7 the immunogen, wherein antibodies secreted by the immune cells comprise the at
8 least one detectable protein or peptide;
- 9 c) immortalizing antibody-producing immune cells isolated from the genetically-
10 modified mammal;
- 11 d) selecting immortalized immune cells isolated from the genetically-modified
12 mammal that secrete antibodies specific to the immunogen; and
- 13 e) preparing a quantity of detectably-labeled monoclonal antibodies from the
14 selected immune cells.

15 In a further aspect, the invention is also directed to a genetically-modified mammal capable of
16 producing a detectably-labeled immunoglobulin in response to immunization by an antigen, the
17 genome of the mammal comprising at least one fusion polynucleotide consisting of a
18 polynucleotide sequence encoding at least one detectable protein or peptide fused with a the
19 kappa immunoglobulin light chain gene, the lambda immunoglobulin light chain gene, an
20 immunoglobulin heavy chain gene, or any combination thereof, wherein antibodies secreted by
21 immune cells of the genetically-modified mammal comprise the at least one detectable protein or
22

1 peptide.

2
3 In a further aspect, the invention is directed to a chimeric, detectably-labeled immunoglobulin
4 molecule comprising at least one fluorescent protein or peptide and at least one fluorescence-
5 quenching or -modulating protein or peptide fused with a component of the immunoglobulin
6 molecule independently selected from either the kappa immunoglobulin light chain, the lambda
7 immunoglobulin light chain, an immunoglobulin heavy chain, or any combination thereof.

8
9 These and other aspects of the present invention will be better appreciated by reference to the
10 following drawings and Detailed Description.

11 BRIEF DESCRIPTION OF THE DRAWINGS

12 Figure 1 shows the beta-galactosidase-binding activity of a chimeric fusion immunoglobulin
13 secreted from 293T cells transfected with nucleic acid encoding a green-fluorescent-protein-
14 labeled heavy immunoglobulin (IgG2) chain and a green-fluorescent-protein-labeled light
15 (kappa) chain hybrid anti-beta-galactosidase immunoglobulin.
16

17
18 Figures 2 A-B show the fluorescence of antibodies in serum from kappa-GFP knock-in mice
19 bound to Protein A/G beads, as compared to those from wild-type mice.

20
21 Figure 3 A-B demonstrate using PCR amplification that mice of the invention may be
22 homozygous or heterozygous for the kappa-GFP gene, using kappa light chain primers (Figure

3A). Use of GFP primers (Figure 3B) confirm the presence or absence of the GFP insert.

DETAILED DESCRIPTION OF THE INVENTION

The inventors herein have discovered a novel and facile method for preparing useful quantities of detectably-labeled polyclonal or monoclonal antibodies to any preselected immunogen. The method spares the need to perform any modification of the immunogen-specific (primary) antibody to provide a detectable label thereon, such as conjugation to a fluorophore or enzyme, as the detectably-labeled antibodies of the invention are inherently labeled as they are expressed and secreted from genetically-modified immune system cells. In its broadest aspect, the invention provides genetically-modified animals and immune cells from such animals in which the constant region of the heavy and/or the light chain components of the antibodies produced by the animals or cells is fused with a detectable polypeptide, such as a fluorescent polypeptide, these fusion protein(s) resulting from the expression of a genetic modification of the heavy and/or light chain genes wherein the polynucleotide encoding the detectable label is incorporated into the respective genes. Such genetically-modified animals or cells are provided such that any antibody expressed and secreted by the animal or cell comprises at least one labeled constant region.

Thus, the mere induction of a humoral immune response generates the desired detectably-labeled antibody.

The detectable labels of the invention are polypeptides, such as proteins or peptides, and they may be introduced into the genome of a mammalian organism by such methods as homologous recombination and transfection, but such methods are not intended to be limiting whatsoever, and

1 one of skill in the art may prepare the construct(s) and modified cells in any appropriate manner.

2 Embryonic stem cells may be so modified such that the genome of the animal resulting therefrom
3 comprises the genetic modification. Several examples provided below are for illustrative
4 purposes only.

5
6 The detectable polypeptide may be, by way of non-limiting example, a fluorescent polypeptide, a
7 visibly-colored polypeptide, a polypeptide with enzymatic activity, or a polypeptide capable of
8 interacting with or binding to another molecule to produce a detectable product. Preferred are
9 labels which require no direct interaction or further sample processing for detectability, and thus
10 are detectable by the application of exogenous methods such as absorbance of light, fluorescence,
11 etc. More preferred are fluorescent polypeptides; most preferred is green fluorescent protein and
12 its polypeptide relatives.

13
14 Moreover, a plurality of detectable labels may be present in the antibodies produced by the
15 animals or cells of the invention. For example, both a fluorescent label and an enzyme label may
16 be appended in tandem to the C-terminus of an immunoglobulin heavy chain gene, such that the
17 resulting expressed and assembled immunoglobulin molecule is detectable both by fluorescence
18 and by histochemistry, by use of a fluorogenic and chromogenic/precipitating substrate of the
19 enzyme, respectively. In another example, the antibody is detectable fluorometrically and by
20 Western blot. As noted above, either or both the heavy and light chain constant regions may be
21 independently modified as described herein, both with the same single or plurality of labels, or,
22 for example, the heavy chain with a fluorescent label and the light chain with an enzyme label.

1 These particular examples of multiple labels on multiple sites of the antibodies are merely
2 illustrative of the range of directly-labeled antibodies that the skilled artisan may be directed to
3 prepare following the teachings herein, and any particular example or embodiment is not
4 intended to be limiting whatsoever.

5
6 Examples of fluorescent polypeptides include but are not limited to green fluorescent protein and
7 other related polypeptide fluorophores which may produce other colors; the availability of
8 individually-detectable primary antibodies in a mixture allows for the simultaneous localization
9 or quantitation of multiple target antigens or analytes in a biological sample. The green
10 fluorescent protein of *Aequorea victoria* is particularly preferred as the fluorescent protein. A
11 cDNA for the protein has been cloned (D. C. Prasher et al., "Primary structure of the *Aequorea*
12 *victoria* green-fluorescent protein," *Gene* (1992) 111:229-33.). *Aequorea* green fluorescent
13 protein ("GFP") is a stable, proteolysis-resistant single chain of 238 residues and has two
14 absorption maxima at around 395 and 475 nm; Excitation at the primary absorption peak of 395
15 nm yields an emission maximum at 508 nm with a quantum yield of 0.72-0.85 (O. Shimomura
16 and F. H. Johnson *J. Cell. Comp. Physiol.* 59:223 (1962); J. G. Morin and J. W. Hastings, *J. Cell.*
17 *Physiol.* 77:313 (1971); H. Morise et al. *Biochemistry* 13:2656 (1974); W. W. Ward *Photochem.*
18 *Photobiol. Reviews* (Smith, K. C. ed.) 4:1 (1979); A. B. Cubitt et al. *Trends Biochem. Sci.*
19 20:448-455 (1995); D. C. Prasher *Trends Genet.* 11:320-323 (1995); M. Chalfie *Photochem.*
20 *Photobiol.* 62:651-656 (1995); W. W. Ward. *Bioluminescence and Chemiluminescence* (M. A.
21 DeLuca and W. D. McElroy, eds) Academic Press pp. 235-242 (1981); W. W. Ward & S. H.
22 Bokman *Biochemistry* 21:4535-4540 (1982); W. W. Ward et al. *Photochem. Photobiol.*

35:803-808 (1982)). Mutants of GFP are embraced herein as they provide certain other characteristics, such as mutation of Serine 65 to Thr (S65T) simplifies the excitation spectrum to a single peak at 488 nm of enhanced amplitude (R. Heim et al. Nature 373:664-665 (1995)), which no longer gives signs of conformational isomers (A. B. Cubitt et al. Trends Biochem. Sci. 20:448-455 (1995)). In another example, U.S. Patent No. 6,077,707 describes a nucleic acid molecule comprising a nucleotide sequence encoding a functional engineered fluorescent protein whose amino acid sequence is substantially identical to the amino acid sequence of *Aequorea* green fluorescent protein but differs by at least a substitution at T203 and, in particular, T203X, wherein X is an aromatic amino acid selected from H, Y, W or F. In one embodiment therein, the amino acid sequence further comprises a substitution at S65, wherein the substitution is selected from S65G, S65T, S65A, S65L, S65C, S65V and S65I. In another embodiment, the amino acid sequence differs by no more than the substitutions S65T/T203H; S65T/T203Y; S72A/F64L/S65G/T203Y; S65G/V68L/Q69K/S72A/T203Y; S72A/S65G/V68L/T203Y; S65G/S72A/T203Y; or S65G/S72A/T203W. In another embodiment, the nucleotide sequence encoding the protein differs from the nucleotide sequence of native green fluorescent protein by the substitution of at least one codon encoding an amino acid substitution at L42, V61, T62, V68, Q69, Q94, N121, Y145, H148, V150, F165, I167, Q183, N185, L220, E222 (not E222G), or V224. In another embodiment, the amino acid substitution is: L42X, wherein X is selected from C, F, H, W and Y, V61 X, wherein X is selected from F, Y, H and C, T62X, wherein X is selected from A, V, F, S, D, N, Q, Y, H and C, V68X, wherein X is selected from F, Y and H, Q69X, wherein X is selected from K, R, E and G, Q94X, wherein X is selected from D, E, H, K and N, N121X, wherein X is selected from F, H, W and Y, Y145X, wherein X is selected from

1 W, C, F, L, E, H, K and Q, H148X, wherein X is selected from F, Y, N, K, Q and R, V150X,
2 wherein X is selected from F, Y and H, F165X, wherein X is selected from H, Q, W and Y,
3 I167X, wherein X is selected from F, Y and H, Q183X, wherein X is selected from H, Y, E and
4 K, N185X, wherein X is selected from D, E, H, K and Q, L220X, wherein X is selected from H,
5 N, Q and T, E222X, wherein X is selected from N and Q, or V224X, wherein X is selected from
6 H, N, Q, T, F, W and Y. These examples are merely illustrative of the wide selection of
7 fluorescent polypeptides and their corresponding polynucleotide sequences that may be employed
8 in the preparation of the genetically-modified cells or animals of the invention.

Another example of a fluorescent protein is red fluorescent protein from coral (Matz et. al., 1999, *Nature Biotechnology* 17:969). Fluorescent peptides or fluorescent protein fragments of these and other fluorescent proteins are also embraced herein. In another example of a detectable polypeptide, polypeptide labels capable of being detected include those containing four cysteines at the i, i+1, i+4, and i+5 positions (i.e., WEAAAREACCRECCARA). These peptides will bind specifically to the fluorescein derivative 4',5'-bis(1,3,2-dithioarsolan-2-yl)fluorescein (FLASH), which is non-fluorescent until bound. The use of such peptides has the advantage of providing fusion proteins of much smaller size than GFP, and fluorescence is easily detected by addition of FLASH (Griffin et. al., 1998, *Science* 281:269). Thus, the use of polypeptides that are capable of specifically binding a detectable label are embraced herein as another embodiment of the present invention.

Examples of polypeptides capable of being detected by enzymatic activity include various

1 enzymes and catalytic polypeptide fragments thereof. Particularly preferred enzymatic labels
2 include those which are able to produce a detectable color or fluorophore in a single step
3 requiring a minimum of reagents, such as alkaline phosphatase, which can cleave a chromogenic
4 substrate, such as p-nitrophenyl phosphate, or a fluorogenic substrate, such as ECF substrate
5 (Amersham/Pharmacia); and a fluorogenic horseradish peroxidase substrate, FluoroBlot (Pierce
6 Chemical Co.). Another example is a fluorescent beta-galactosidase substrate that can be used in
7 live cells and is 100-fold more sensitive than GFP (Zlokarnik et. al., 1988, *Science* **279**:85). The
8 skilled artisan by the teachings herein will be amply aware of polynucleotides that may be fused
to the immunoglobulin constant region(s) and upon expression produce an enzymatically-active
fusion polypeptide comprising the immunoglobulin heavy and/or light chain.

Such labels may also result in the precipitation of a substrate, for histochemical localization of
the antibody, or the label may interact with another detectable component, and thus be, for
example, an intein, a biotin-binding subunit of streptavidin or avidin, a His tag, or a chitin-
binding domain.

16
17 Guidance for the selection of the immunoglobulin genes and locations therein in which to fuse
18 the detectable polypeptide(s) of the invention may be performed as follows. As is well known,
19 the antibody molecule is composed of two heavy chains and two light chains. Each chain has a
20 two identical variable regions which bind antigen, and a constant region. The N-terminus of both
21 chains is part of the variable region and the C-terminus is part of the constant region.

1 The genomic organization of heavy chain contains a number of repeats of V, D, and J regions
2 upstream of several constant regions. The different constant regions define the eventual antibody
3 class (e.g., IgG1, IgG2a, IgA, etc). During B-cell maturation, a single V, D, and J are joined to
4 form a single exon. Additionally, late in B-cell development, a single constant region is chosen in
5 a process called "class switching". Each constant region contains a number of exons. After
6 transcription, the VDJ and constant regions are spliced into the mature mRNA.

7
8 To generate the fusion protein of the invention, a polynucleotide encoding the detectable
9 polypeptide is inserted into the constant region, or preferably, is appended to portion of the gene
10 resulting in the expression of the fused polypeptide label on the C-terminus of the constant region
11 of the light and/or heavy chains, optionally with a flexible linker peptide.

12
13 There are two classes of light chains, kappa and lambda. Kappa comprises 95% of antibodies,
14 lambda 5%. Furthermore, there are two forms of each class of the heavy chain—a secreted and a
15 membrane bound form. The membrane bound form is responsible for signaling to the B-cell
16 when it is crosslinked by an antigen and is required for B-cell maturation and antibody
17 production. The two forms result from alternative splicing. Preferably, only the secreted form is
18 modified as described herein. The membrane bound form would be completely wild type, to
19 maintain fidelity of generation of the antibody response.

20
21 Thus, an immune cell with the genetic modifications described herein may secrete
22 immunoglobulin that may have possess a detectable polypeptide label fused in the heavy chain

1 constant region, or a detectable polypeptide label fused in the light chain constant region, or the
2 immunoglobulin may have both a heavy and light chain fusion component. Moreover, each
3 detectable label may be a single detectable label or a plurality of labels, in tandem or not,
4 optionally separated from the immunoglobulin portion of the polypeptide by one or more linker
5 sequences. The label on the heavy chain may be the same or different from that on the light
6 chain, for immunoglobulins that have both heavy and light chains as fusion products. Although
7 the placement of the detectable label is preferably on or near the C-terminus, the fused label(s)
8 may be at any position(s) with does not detract from the ability of the immunoglobulin to interact
9 with and bind to its target antigen. The invention herein embraces any and all variations in the
10 position, placement, linkers, and number of fused peptides or polypeptides, with the object of the
11 invention to provide at least one detectable label on an immunoglobulin molecule generated by
12 exposure of an animal or immune cell with the aforementioned genetic modification to any
13 immunogen capable of eliciting secretion of an antibody directed thereto.

14
15 As described above, a mammalian organism, such as a mouse, rat, rabbit, goat, cow, horse, may
16 be provided with the genetic modification as described herein. Example 4 below demonstrates
17 the invention using mice, in which endogenous production of fluorescent antibodies is shown.
18 Exposure of the animal to a preselected immunogen will elicit an antibody response, the secreted
19 antibodies having the detectable label(s) present in every antibody molecule. For production of
20 polyclonal antibodies, antiserum from the immunized animals may be collected, the antibodies
21 purified if desired, for subsequent use in such areas as histochemistry, diagnostics, etc.
22

1 If detectably-labeled primary monoclonal antibodies are desired, routine methods may be
2 followed using an animal, such as a mouse, with the genetic makeup hereindescribed. B-cells
3 secreting the detectably-labeled primary antibodies may be fused for immortalization, and
4 screening and selection for stable antibody-secreting hybridomas obtained by routine methods.

5
6 Of course, detectably-labeled primary anti-idiotypic antibodies may be prepared by the foregoing
7 methods, using antibodies as immunogen.

8
9 As mentioned above, the polyclonal and monoclonal antibodies generated by the methods
10 described herein have several advantages, including 1) because the primary antibody is
11 endogenously fluorescent, no secondary antibody or chemical labeling is required, 2)
12 autofluorescent proteins are currently available in several different colors, including blue, cyan,
13 green, yellow, and red, allowing for simultaneous labeling of several antigens, and simultaneous
14 detection by instrumentation capable of discriminating several fluorophores simultaneously. In
15 addition, the availability of two different means for detection, such as but not limited to a visibly-
16 detectable and enzymatically-detectable marker, provides detectability under a variety of
17 conditions, applicable to various research and diagnostic applications, among others.

18
19 Introduction of the genetic modification(s) described herein into an embryonic stem cell or other
20 cell type may be achieved by a variety of procedures known in the art. Preferably, the genetic
21 modification is introduced by a "knock-in" procedure in which the wild-type immunoglobulin
22 gene(s) are replaced by the detectable-label-modified genes. Such procedures may include the

1 use of a bacterial artificial chromosome, as exemplified in Example 2 below, although this
2 example is merely illustrative and non limiting as to procedures for achieving the genetically-
3 modified mammal or mammalian cells of the invention.

4
5 Antigens to which detectable antibodies may be raised in genetically-modified animals or
6 immune cells as described herein are not limited to any particular types or classes of immunogen,
7 and includes those for which a detectable antibody is desirable. Such antigens comprise a vast
8 list. By way of non-limiting example, this includes diagnostic and research reagents for
9 identifying the presence of and/or quantitating various medically-important biomolecules in
10 bodily fluids, biopsy and necropsy samples, for example, all diagnostic tests which employ
11 immunoassay protocols, including ELISA, radioimmunoassay, EMIT, immunofluorescence,
12 fluorescence polarization, and other methods for detecting the interaction between and
13 biomolecule of interest and an antibody thereto. Medical diagnostics include, by way of non-
14 limiting example, assays for autoimmune disorders, cardiovascular disorders, diabetes, endocrine
15 disorders, fungal, bacterial, viral, parasitic, and other infectious agents, hematologic diseases,
16 immunologic diseases, hepatic diseases, oncologic diseases, thyroid diseases, and toxicology and
17 drugs of use and abuse. Moreover, as mentioned above, the ability to discriminate between
18 differently labeled primary antibodies without the need for, and concomitant disintegration of
19 signal, by multiple secondary antibodies, will permit multiple analytes to be measured
20 simultaneously, decreasing the costs and increasing the amount of information available for
21 rendering diagnostic and therapeutic decisions. In the research area, innumerable new and
22 known biomolecules to which antibodies are routinely raised for identifying the location,

1 movement, transport, role, etc., of such new or rediscovered biomolecules in biological processes
2 will be simplifiable, as well as permit the simultaneous and facile monitoring of multiple
3 biomolecules using differently-labeled antibodies to several biomolecules participating in a
4 process. The discussion herein on particular antigens is not intended to be at all limiting but is
5 merely illustrative of some examples of the utility of the invention.
6

7 In another example of the invention, a genetically-modified mammal may be prepared which
8 responds to immunization with an antigen by the production of chimeric immunoglobulin
9 molecules capable of reading out a signal or altering the signal produced only on binding with the
10 target antigen. This signal may be, for example, an increase, decrease or change in fluorescence.
11 Such chimeric antibodies may be used in a very simple homogeneous immunoassay in which, on
12 combining with a sample, indicates the presence or extent of the level of the antigen in the
13 sample. Pairs of proteins or peptides capable of undergoing such modulation in fluorescence
14 include FRET pairs, such as described, for example, in U.S. Patent 5,998,204, incorporated
15 herein by reference in its entirety.
16

17 Such chimeric antibodies are prepared by following the methods described herein. In the
18 example wherein the fluorescence is detected, the genes encoding the chains of the secreted
19 immunoglobulin are modified at the polynucleotide level to provide that both a fluorescent
20 peptide or polypeptide, and a fluorescence-quenching or -modulating peptide or polypeptide, are
21 fused into either the heavy immunoglobulin chain or the light immunoglobulin chain in the
22 appropriate position in the genome of the mouse. The positions of integration into the respective

1 immunoglobulin components are such that the proximity of the fluorescent polypeptide and the
2 fluorescence-quenching or -modulating polypeptide in the secreted, whole immunoglobulin
3 molecule, change on binding of the immunoglobulin to its target antigen. This change in
4 proximity alters the interaction between the fluorophore and the quencher or modulator resulting
5 in a modulation in the detectable fluorescence on exposure of the immunoglobulin to its
6 excitation wavelength. Such positions are selected to not alter the ability of the complete
7 immunoglobulin molecule to assemble, be secreted, or bind the antigen. These selections are
8 within the realm of the skilled artisan. Known fluorescent peptides or polypeptides as well as
9 peptides and polypeptides capable of quenching or modulating the fluorescence, such as FRET
10 pairs, are known and can be selected to provide the chimeric immunoglobulin, and mammals
11 capable of producing the immunoglobulin after immunization.

12 The present invention may be better understood by reference to the following non-limiting
13 Examples, which are provided as exemplary of the invention. The following examples are
14 presented in order to more fully illustrate the preferred embodiments of the invention. They
15 should in no way be construed, however, as limiting the broad scope of the invention.
16

17 Example 1

18 **Secretion of detectably-labeled antibodies**

19
20
21 A rat IgG2A antibody hybridoma which produces a monoclonal antibody reactive against
22 beta-galactosidase was used to determining whether GFP fusion proteins would be correctly

1 assembled, secreted, and recognize antigen. The cDNA of the secreted form of the heavy and
2 light chains against beta-galactosidase were cloned. The polynucleotide sequence encoding GFP
3 was placed in front of the stop codon of both the heavy chain of IgG2A and light kappa chains.
4 The plasmid combinations of 1) non-GFP tagged, 2) IgG2A heavy chain tagged, 3) light chain
5 tagged, and 4) both heavy chain and light chain tagged, were transfected into 293T kidney cells
6 and tested for ability to bind antigen.

7
8 The 293T cells do not express any endogenous antibodies. They were transfected with two
9 expression vectors of combinations of IgG2A and kappa chains against beta-galactosidase: 1)
10 IgG2A and kappa; 2) IgG2A and kappa-GFP; 3) IgG2A-GFP and kappa; and 4) IgG2A-GFP and
11 kappa-GFP. The transfected cells will express and assemble and secrete the complete antibody.
12 Forty-eight hours after transfection, the medium was harvested. This contained unpurified
13 antibodies which was used for the experiments below

14
15 Confirmation of the secretion of the detectably-labeled antibody was obtained in several
16 experiments. In one experiment, cells were fed radiolabeled ^{35}S methionine after transfection and
17 newly synthesized proteins were labeled. The secreted proteins were collected. Two fractions
18 were evaluated, one that bound to Protein G and one that bound to beta-galactosidase
19 immobilized on beads. Protein G is a toxin which binds antibodies. As shown in **Figure 1**, both
20 GFP-tagged and untagged antibodies bound to Protein G and to beta-galactosidase. The affinity
21 and specificity towards beta-galactosidase appears greater. Thus, the antibody recognizes antigen
22 and is correctly folded. When only light chain or heavy chain but not both are transfected, the

1 chains did not bind to either protein G or beta-galactosidase. When examined under the
2 microscope, the beads were bright green, showing that the GFP is correctly folded and
3 fluorescent.

4 **Example 2**

5 **Preparation of genetically-modified (knock-in) animals comprising** 6 **detectably-labeled immunoglobulin genes**

7
8 Knock-in or gene replacement involves replacing an endogenous piece of DNA in the
9 chromosome with a constructed piece of DNA. Thus, the constructed DNA must correctly
10 integrate into the same genetic location as the gene to be replaced. This is distinctly different
11 from transgenic technology where a constructed DNA is randomly introduced into a cell.

12
13 I. Construction of a segment of bacterial plasmid DNA that contains the change of interest and
14 extensive homology to the target. Generation of the IgG1-GFP fusion knock-in construct is
15 described below. The VDJ variable regions of the IgG1 constant chain are far upstream (5') of
16 this area. Immediately upstream of this area are the IgM and IgD constant regions. Downstream
17 to this area are the constant regions for IgG2a, IgG2b, IgG3, IgE, and IgA. The exons CH1, CH2
18 and G1 are spliced together to make the constant region of the secreted form. To make the
19 membrane bound form, CH1, CH2, G1 (except the last 2 amino acids), TD1, and TD2 are spliced
20 together. In the targeting vector, GFP is fused in-frame at the end of the G1 exon with a five-
21 amino-acid linker of Gly-Gly-Ser-Gly-Gly in-between. The membrane bound form splices out
22 the last two amino acids of G1 and thus the entire GFP. Therefore, GFP will be fused only to the

1 secreted form.

2
3 A bacterial artificial chromosome (BAC) containing the entire IgG region is obtained. The
4 targeting vector contains the 5' homologous region directly PCR'd from the BAC. The G1-GFP
5 fusion is generated by primer overlap extension PCR (Horton et al., 1990; Horton, 1995). A
6 neomycin resistance gene is introduced as a selection marker. This neomycin gene is flanked on
7 each side by a loxP site. Thus, after selection, the gene is deleted by Cre-mediated
8 recombination. This eliminates problems due the presence of the neomycin gene and its
9 associated promoter (Zou et al., 1993). A 3' homologous region is also PCR'd from the BAC.
10 Finally, a toxic gene, diphtheria toxin (DTA) is introduced just outside the area of homology.
11 Homologous recombination between the targeting vector and the targeting region cuts out the
12 toxin gene. Non-homologous random integration events often retain DTA and the cells will be
13 killed (Yagi et al., 1990; Yagi et al., 1993; McCarrick, III et al., 1993).

14
15 After preparation, embryonic stem cells are transfected with the targeting vector and selection
16 with neomycin analog G418 is performed. Clones are screened for correct integration by
17 Southern analysis and PCR. Subsequently, correctly targeted ES cell are injected into blastocysts
18 and implanted into mothers. The blastocysts develop into chimeric mice, where some cells are
19 developed from the injected ES cells. The chimeras are used to parent heterozygote mice. Two
20 heterozygous mice are then parented to produce homozygous mice.

21
22 The mouse IgG1 heavy chain and kappa light chains have been previously targeted for gene

1 replacement. In those cases, the constant chain was replaced with human constant chains and the
2 resulting mice generated humanized antibodies (Zou et al., 1993; Zou et al., 1994).

3
4 **Production of Monoclonal Antibodies.** Mice as prepared above are inoculated with the antigen
5 of interest. After several weeks, the antibody production against the antigen is screened, as
6 traditionally done with an ELISA, where the antigen is immobilized, the mouse serum is added,
7 and an enzyme-linked secondary antibody against the primary is added. The presence of
8 enzymatic activity indicates that the mouse has produced specific antibodies. Since here, the
9 antibodies are already fluorescent, an ELISA is unnecessary and measurement of bound
10 fluorescence is sufficient. Fusion of splenocytes from a positive mouse with myeloma cells is
11 used to produce immortalized antibody-producing cells, following standard protocols. Further
12 screening of colonies can be performed using simple fluorescence measurements.

13
14
15 Antibody may be produced in quantity by growth of cell-hybrids, following standard protocols.

16 **Example 3**

17 **Homogeneous immunoassays using detectably-labeled antibodies**

18 **from a genetically-modified mouse**

19
20 In a further example of the methods described in Example 2, above, a genetically-modified
21 mouse may be prepared which responds to immunization with an antigen by the production of
22 chimeric immunoglobulin molecules capable of reading out a signal only on binding with the

1 target antigen. Such chimeric antibodies may be used in a very simple homogeneous
2 immunoassay in which, on combining with a sample, indicates the presence or extent of the level
3 of the antigen in the sample.

4 Such chimeric antibodies are prepared by following the methods herein. Both a fluorescent
5 peptide or polypeptide, and a fluorescence-quenching peptide or polypeptide, are fused into
6 either the heavy immunoglobulin chain or the light immunoglobulin chain in the appropriate
7 position in the genome of the mouse. Such pairs may include FRET pairs or proteins, such as
8 described, for example, in U.S. Patent 5,998,204, incorporated herein by reference in its entirety.

9 The positions of integration into the respective immunoglobulin components are such that the
10 proximity of the fluorescent polypeptide and the fluorescence-quenching polypeptide change on
11 binding of the immunoglobulin to its target antigen. Such positions also do not alter the ability
12 of the complete immunoglobulin molecule to assemble, be secreted, or bind the antigen. Both
13 the fluorescent and the fluorescence-quenching protein or peptides may be fused into the same
14 immunoglobulin component, at positions wherein antigen binding induces a conformational
15 change and thus a proximity change among the pair and attendant modulation of fluorescence.
16

17 Examples of fluorescent peptides and proteins are described above. In this example, the mouse
18 was genetically modified such that IgG2 heavy chains included the). Suitable pairs, for example
19 include a blue-shifted GFP mutant P4-3 (Y66H/Y145F) as the donor, and an improved green
20 mutant S65T can respectively serve as a donor and an acceptor for fluorescence resonance energy
21 transfer (FRET; Tsien et al., 1993, Trends Cell Biol. 3:242-245). A genetically-modified mouse
22 expressing antibodies with these modifications was immunized with human chorionic

1 gonadotropin (hCG). The fluorescence of antibodies produced by this mouse was increased upon
2 binding to hCG. This reagent was used in a simplified assay in an automated fluorescence-based
3 instrument for determining pregnancy among a large battery of other diagnostic tests on blood
4 and urine samples.

6 Example 4

7 **Kappa-GFP knock-in mice produce fluorescent endogenous antibodies**

8
9 Kappa-GFP knock-in mice were prepared in accordance with the methods described in Example
10 2, above. At 8 weeks of age, animals were bled and serum was incubated with Protein A/G
11 beads, to which antibodies in the serum bind. As shown in **Figure 2**, under fluorescence
12 illumination the beads showed the characteristic fluorescence of GFP (**Figure 2A**), whereas
13 serum from wild-type mice incubated with Protein A/G beads did not (**Figure 2B**). Thus, the
14 mice produced fluorescently-labeled, endogenous immunoglobulin molecules, comprising kappa-
15 GFP, fluorescent light chains.
16

17 Example 5

18 **Confirmation of genotype using PCR for kappa and GFP**

19
20 Figure 3 shows the results of PCR amplification using primers from up- and down-stream of the
21 section of the kappa light chain where the GFP was targeted (Figure 3A), or using GFP primers
22 (Figure 3B), from DNA extracts from a number of mice prepared in accordance with the present

1 invention. The segment amplified from wild type kappa light chains is the smallest and runs
2 the fastest on the gel (as indicated). The segment amplified with the GFP insert is larger and
3 migrates slower.

4
5 In Figure 3A, using the kappa primers, lane 2 has only the faster moving product and is therefore
6 from a mouse that is homozygous for wild-type kappa light chain. Lanes 3, 5, and 7-12 have
7 both products, which indicates that the mice are heterozygous. Lanes 1, 4, and 6 only have the
8 slower moving product indicating that they are homozygous for the kappa with the inserted GFP.

9
10 Figure 3B shows using primers from the GFP coding region that lane 2 was negative for GFP,
11 consistent with the observation that this mouse did not produce a PCR product from kappa-GFP.
12 Lanes 1 and 2-12 were positive for GFP, consistent with the results from the top panel.

13
14 The present invention is not to be limited in scope by the specific embodiments describe herein.
15 Indeed, various modifications of the invention in addition to those described herein will become
16 apparent to those skilled in the art from the foregoing description and the accompanying figures.
17 Such modifications are intended to fall within the scope of the appended claims.

18
19
20 It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or
21 molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided
22 for description.

1 Various publications are cited herein, the disclosures of which are incorporated by reference in
2 their entireties.

3
4 Horton,R.M. (1995). PCR-mediated recombination and mutagenesis. SOEing together
5 tailor-made genes. Mol. Biotechnol. 3, 93-99.

6
7 Horton,R.M., Cai,Z.L., Ho,S.N., and Pease,L.R. (1990). Gene splicing by overlap extension:
8 tailor-made genes using the polymerase chain reaction. Biotechniques 8, 528-535.

9
10 McCarrick,J.W., III, Parnes,J.R., Seong,R.H., Solter,D., and Knowles,B.B. (1993).
11 Positive-negative selection gene targeting with the diphtheria toxin A- chain gene in mouse
12 embryonic stem cells. Transgenic Res. 2, 183-190.

13
14 Yagi,T., Ikawa,Y., Yoshida,K., Shigetani,Y., Takeda,N., Mabuchi,I., Yamamoto,T., and
15 Aizawa,S. (1990). Homologous recombination at c-fyn locus of mouse embryonic stem cells
16 with use of diphtheria toxin A-fragment gene in negative selection. Proc. Natl. Acad. Sci. U. S. A
17 87, 9918-9922.

18
19 Yagi,T., Nada,S., Watanabe,N., Tamemoto,H., Kohmura,N., Ikawa,Y., and Aizawa,S. (1993). A
20 novel negative selection for homologous recombinants using diphtheria toxin A fragment gene.
21 Anal. Biochem. 214, 77-86.

1 Zou,Y.R., Gu,H., and Rajewsky,K. (1993). Generation of a mouse strain that produces
2 immunoglobulin kappa chains with human constant regions [see comments]. Science 262,
3 1271-1274.

4
5 Zou,Y.R., Muller,W., Gu,H., and Rajewsky,K. (1994). Cre-loxP-mediated gene replacement: a
6 mouse strain producing humanized antibodies. Curr. Biol. 4, 1099-1103.

7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100